Inflammatory bowel disease (IBD), affecting an estimated 6–8 million people worldwide, may soon be monitored with a simple ...

A new therapy that combines two existing drugs shows promise for patients with inflammatory bowel disease who have exhausted ...

The FDA issued a priority voucher promising a quick review of zenocutuzumab (Bizengri) for previously treated advanced, ...

A new combination drug therapy could help people with inflammatory bowel disease (IBD) for whom other medicines have stopped ...

Epirium Bio Inc. (Epirium), a clinical-stage biopharmaceutical company advancing medicines for neuromuscular, inflammatory, and fibrotic diseases, is presenting new translational data on its oral ...

Targeted dietary therapies can induce remission in 50%-80% of IBD patients; discover which protocols — EEN, CDED, and whole ...

This study validates criteria to identify patients with inflammatory bowel disease (IBD) at risk of worsening disease who may benefit from early treatment with advanced therapies. Objectives: Risk ...

The occurrence of microscopic colitis in Sweden has risen steadily over the past decades, according to a new study from ...

Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, affects millions and can be life-altering. Beyond medications, research highlights the role of gut microbiome health ...

KT-579 demonstrated activity comparable or superior to approved and clinically active therapies in preclinical IBD models KT-579 Phase 1 healthy volunteer trial ongoing, with data expected in 2H26 ...

Dr Susan Brannick, clinical psychologist with expertise in inflammatory bowel disease (IBD) and clinical director of mental ...